

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

CHANGE IN SHAREHOLDING

This is a voluntary announcement made by the Company.

The Company was informed by GS Corp that on 17 October 2017, each of Dr. Zhang and Ms. Wang transferred 5 million shares and 2.5 million shares of GS Corp to the Zhang Trust and the Wang Trust, respectively. As at 17 October 2017, GS Corp directly held 890,902,024 Shares, representing approximately 51.52% of the entire issued share capital of the Company.

Immediately after the Transfers, each of the Zhang Trust (through its trustee) and the Wang Trust (through its trustee) will be deemed, or taken to be interested in, all the Shares held by GS Corp.

The Board considers that the Transfers will not have any impact on the financial position and operations of the Company and its subsidiaries.

This is a voluntary announcement made by the Company.

THE TRANSFERS

The Company was informed by GS Corp that on 17 October 2017, each of Dr. Zhang and Ms. Wang transferred 5 million shares and 2.5 million shares of GS Corp to their respective family trusts. As at 17 October 2017, GS Corp directly held 890,902,024 Shares, representing approximately 51.52% of the entire issued share capital of the Company.

The Zhang Trust

Dr. Zhang set up the Zhang Trust on 12 October 2017, an irrevocable discretionary family trust, with his three children and their respective living issue as beneficiaries. Ms. Jin is the trustee of the Zhang Trust.

Immediately before the Zhang Transfer, Dr. Zhang held approximately 40.59% of the entire issued share capital of GS Corp and was deemed, or taken to be interested in, all the Shares held by GS Corp for the purpose of the Securities and Futures Ordinance.

Immediately after the Zhang Transfer: (a) the Zhang Trust (through its trustee) will hold in aggregate 5 million shares of GS Corp, collectively representing approximately 1.08% of the entire issued share capital of GS Corp; and (b) the Zhang Trust will be deemed, or taken to be interested in, all the Shares held by GS Corp.

The Wang Trust

Ms. Wang set up the Wang Trust on 5 October 2017, an irrevocable discretionary family trust, with her spouse, her son and his living issue as beneficiaries. Mr. Hu is the trustee of the Wang Trust.

Immediately before the Wang Transfer, Ms. Wang held approximately 11.76% of the entire issued share capital of GS Corp.


Immediately after the Wang Transfer: (a) the Wang Trust (through its trustee) will hold in aggregate 2.5 million shares of GS Corp, collectively representing approximately 0.54% of the entire issued share capital of GS Corp; and (b) the Wang Trust will be deemed, or taken to be interested in, all the Shares held by GS Corp.

REASONS FOR THE TRANSFERS


The Transfers are for their respective family wealth and succession planning purposes of Dr. Zhang and Ms. Wang.

SHAREHOLDING STRUCTURE

Immediately before the Transfers



Immediately after the Transfers



IMPLICATIONS

Immediately after the Transfers, each of the Zhang Trust (through its trustee) and the Wang Trust (through its trustee) will be deemed, or taken to be interested in, all the Shares held by GS Corp.

The Board considers that the Transfers will not have any impact on the financial position and operations of the Company and its subsidiaries.

DEFINITIONS

“Board”	the board of directors of the Company;
“Company”	Genscript Biotech Corporation (金斯瑞生物科技股份有限公司), an exempted company incorporated under the laws of the Cayman Islands with limited liability on 21 May 2015, whose shares are listed on the main board of the Stock Exchange (Stock Code: 1548);
“Dr. Zhang”	Dr. Zhang Fangliang, an executive Director of the Company;
“GS Corp”	Genscript Corporation, a company incorporated on 3 July 2002, under the laws of the State of Delaware of the United States;
“Mr. Hu”	Mr. Zhiyong Hu, the spouse of Ms. Wang;
“Ms. Jin”	Ms. Weihong Jin, the spouse of Dr. Zhang;
“Ms. Wang”	Ms. Wang Ye, an executive Director of the Company;
“Shares”	ordinary shares of par value US\$0.001 each in the share capital of the Company;
“Stock Exchange”	the Stock Exchange of Hong Kong Limited;
“Transfers”	the Zhang Transfer and the Wang Transfer;
“Wang Transfer”	the transfer of the aggregate 2.5 million shares of GS Corp by Ms. Wang to the Wang Trust at nil consideration, collectively representing approximately 0.54% of the entire issued share capital of GS Corp;
“Wang Trust”	an irrevocable discretionary trust established by Ms. Wang on 5 October 2017 for the benefit of her spouse, her son and his living issue;

- “Zhang Transfer” the transfer of the aggregate 5 million shares of GS Corp by Dr. Zhang to the Zhang Trust at nil consideration, collectively representing approximately 1.08% of the entire issued share capital of GS Corp; and
- “Zhang Trust” an irrevocable discretionary trust established by Dr. Zhang on 12 October 2017 for the benefit of his three children and their respective living issue.

By Order of the Board
Genscript Biotech Corporation
Dr. Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 17 October 2017

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Huang Zuie-Chin and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.

** For identification purposes only*